Is MUSTANG BIO, INC. (MBIO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 13.4% / 30% | 104.5% / 30% | 6.1% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 13.4% / 33% | 104.5% / 33% | 6.1% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 9.4% / 33% | 73.5% / 33% | 4.3% / 33% | N/A | ✗ NOT HALAL |
| S&P | 13.4% / 33% | 104.5% / 33% | 6.1% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 9.4% / 33% | 73.5% / 33% | 4.3% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -67.9% | |
| Return on Assets (ROA) | -11.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$11M |
| Free Cash Flow | -$11M |
| Total Debt | $878,000 |
| Current Ratio | 2.2 |
| Total Assets | $9M |
Price & Trading
| Last Close | $0.74 |
| 50-Day MA | $0.92 |
| 200-Day MA | $1.34 |
| Avg Volume | 185K |
| Beta | 2.1 |
|
52-Week Range
$0.53
| |
About MUSTANG BIO, INC. (MBIO)
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is MUSTANG BIO, INC. (MBIO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), MUSTANG BIO, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is MUSTANG BIO, INC.'s debt ratio?
MUSTANG BIO, INC.'s debt ratio is 13.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 9.4%.
What are MUSTANG BIO, INC.'s key financial metrics?
MUSTANG BIO, INC. has a market capitalization of $5M. Return on equity stands at -67.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.